Joshua Reuss
@Joshua_Reuss
Thoracic Medical Oncologist @lombardicancer, Assistant Professor @Georgetown. Interested in immunotherapy translational clinical trials. Opinions are my own.
Make plans for #DCLung25 - Saturday, October 4th - Washington DC - a one-day @IASLC endorsed comprehensive lung cancer conference! Dr. Cristina Merkhofer joins to discuss best practice for advanced squamous NSCLC. Register today! Trainees attend free! medstarhealth.org/dclung25
🔥🚨Hot Off the Press #BigNews Press Release by @AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in…
Join us at #DCLung25 on Saturday, October 4th in downtown Washington, DC for the latest updates in lung cancer. Dr. Christine Lovly @christine_lovly joins the faculty to discuss biomarkers for NSCLC. @IASLC endorsed & CME / MOC credits - register today! medstarhealth.org/dclung25
Update to the @ASCO Living Guidelines for NSCLC with driver alterations now @JCO_ASCO from @Joshua_Reuss et al to include zenocutuzumab for patients with NSCLC that harbors an #NRG1 fusion. ascopubs.org/doi/10.1200/JC…
Out now in @JCO_ASCO, v2025.1 of @ASCO Living Guideline for Stage 4 NSCLC w/ driver mutation. ascopubs.org/doi/pdf/10.120…. key updates: ✅incorporation of zenocutuzumab for NRG1-fusion+ NSCLC. ✅commentary on ph2 RAMOSE trial. For concise summary, ✔️ out @ASCO guidelines podcast
Be sure to attend #DCLung25 - Saturday, October 4th in Washington DC: a one-day @IASLC endorsed lung cancer conference with experts like Dr. Shirish Gadgeel @ShirishGadgeel, who will discuss the evolving treatment paradigms of SCLC. Register today! medstarhealth.org/dclung25
Make plans for #DCLung25 - Saturday, October 4th - Washington DC - a one-day @IASLC endorsed comprehensive lung cancer conference! Dr. Zosia Piotrowska @ZPiotrowskaMD joins to discuss targeting EGFR exon 20 and atypical mutations. Register today! medstarhealth.org/dclung25
Join us at #DCLung25 on Saturday, October 4th in downtown Washington, DC for the latest updates in lung cancer. Dr. Charu Aggarwal @CharuAggarwalMD joins the faculty to discuss early stage NSCLC. @IASLC endorsed & CME / MOC credits - register today! medstarhealth.org/dclung25
Meet me in DC. I'll be the very caffeinated person running to attend the presentations of all of the brilliant people I follow here. Let's discuss quality of life off of the web: QOL in IRL , and any more acronyms you can think up, I'm up for it. #LungCancer @EGFRResisters…
Register now for #DCLung25 - a can't miss, one-day, @IASLC endorsed lung cancer conference on Saturday, October 4th in Washington DC. Hear from experts like Dr. Ben Levy @benlevylungdoc, who will discuss targeting HER2, BRAF, and MET in NSCLC. medstarhealth.org/dclung25
🔍 We’re looking for the next wave of leaders in EGFR-mutated NSCLC! Submit your abstract or career statement and join us Nov 6–8 in Chicago. 🗓 Deadline: Aug 8 Register here: ceconcepts.com/egfr-summit @ZPiotrowskaMD @jillfeldman4 #LungCancer #LungCancerResearch #EGFR #EGFRSummit
Make plans for #DCLung25 - Saturday, October 4th - Washington DC - a one-day @IASLC endorsed comprehensive lung cancer conference! Dr. Alfredo Addeo @Alfdoc2 joins from Switzerland to discuss bispecific antibodies and lung cancer. Register today! medstarhealth.org/dclung25
Be sure to attend #DCLung25 - Saturday, October 4th in Washington DC: a one-day @IASLC endorsed lung cancer conference with experts like Dr. Christian Rolfo @ChristianRolfo, who will overview the role of liquid biopsy in lung cancer. Register today! medstarhealth.org/dclung25
Make plans for #DCLung25 - Saturday, October 4th - Washington DC - a one-day @IASLC endorsed comprehensive lung cancer conference! Dr. Marina Garassino @marinagarassino joins with the latest updates in immunotherapy for NSCLC. Register today! medstarhealth.org/dclung25
#DCLung25 is a 1-day, @IASLC endorsed comprehensive lung cancer conference, Saturday, Oct 4th, Washington DC. A great time to visit our nation's capital & learn from the top lung cancer experts in the world! CME, MOC, nursing, pharmacy credits offered! medstarhealth.org/dclung25
Brigatinib post crizotinib in #ALK NSCLC @ClinicalLung from @LudaBazhenovaMD. High response rates seen independent of secondary ALK mutations but if alterations seen in non-ALK secondary drivers (EGFR, KRAS, BRAF, MET0, no responses seen. clinical-lung-cancer.com/article/S1525-…
💥 First trial to demonstrate OS benefit in SCLC in the maintenance setting. Lurbinectedin + Atezolizumab hits in ORR, DoR, PFS, and OS. AEs related to lurbi known tox profile. #LCSM #ASCO25 @SclcSMASHERS